Did Toronto Drug-Checking Clients Usually Expect a Nitazene?
People submitting nitazene-positive samples to Toronto’s drug-checking service usually expected an opioid, but rarely named a nitazene specifically. The distinction comes from the submitter’s reported expectation, not from a laboratory prediction.
What did the service receive?
Gelgoot and colleagues analyzed Canadian drug-checking and seizure data. Toronto’s service detected nitazenes in 489 submitted samples. Among these, 453 were expected by submitters to be an opioid. Only two of those opioid-expected samples were specifically expected to be a nitazene; fentanyl was the stated expectation for 417.
What does the discrepancy mean?
It illustrates why a broad expectation such as “fentanyl” cannot specify the actual full chemical contents. Some samples could contain more than one opioid or other substance. The service also received used equipment as well as drug samples, so the data do not equal a random survey of all products sold in Toronto.
What remains unknown?
A submitter’s expectation may reflect a label, seller description or personal belief; the study does not establish which. These findings do not measure how often every purchaser unknowingly receives nitazenes. For a particular product, the supported question is what the sample’s actual analytical result shows, with the service’s sampling limits stated.
Scientific source: Gelgoot EA, Scarfone KM, Maghsoudi N, et al. The Detection of Novel Nitazene-Class Opioids in Unregulated Drug Markets in Canada. Drug and Alcohol Review. 2026;45:e70189. doi:10.1111/dar.70189



